The identification of an IRE in the 5′UTR of the APP transcript led to a novel therapeutic approach aimed at reducing amyloidosis by several FDA-pre-approved drugs targeted to the IRE in the APP mRNA 5′UTR [91,92]. The gene discussed is APP; the disease is amyloidosis.